Few developments in the modern gem trade have generated as much commercial disruption — or as much confused commentary — as the rapid rise of lab-grown diamonds. In the space of approximately eight years, what was a niche product aimed at industrial applications has become a mainstream consumer jewelry category with a global retail presence that has fundamentally altered the economics of the natural diamond market. For collectors and investors in natural diamonds, understanding what has happened and what it means requires separating the signal from the considerable noise.
The Price Compression: What the Data Actually Shows
The price of laboratory-grown diamonds — produced primarily through Chemical Vapor Deposition (CVD) or High Pressure High Temperature (HPHT) processes — has fallen with extraordinary speed since approximately 2016, when economies of scale in production began to catch up with demand growth. Industry tracking data from Edahn Golan Diamond Research & Data and Paul Zimnisky Diamond Analytics paints a consistent picture.
In 2016, a one-carat F-VS1 laboratory-grown diamond retailed at approximately sixty to seventy percent of the price of a comparable natural stone. By 2019, that ratio had fallen to roughly twenty to thirty percent. By 2022, wholesale prices for laboratory-grown rounds of one to two carats had declined to less than five percent of natural diamond equivalents at comparable quality grades. A two-carat F-VS1 round brilliant that might carry a natural diamond wholesale price of $12,000 or more was available as a laboratory-grown equivalent at wholesale prices of $500 to $800.
The price compression has not stabilized. Production capacity — particularly from Chinese manufacturers who entered the CVD and HPHT space aggressively after 2018 — has continued to expand at rates that exceed demand growth in most market segments. The trajectory of laboratory-grown diamond pricing is toward the marginal cost of production, which is estimated to be in the range of $300 to $400 per carat for competent producers at standard qualities, with further reductions likely as technology matures.
De Beers and the Lightbox Pivot
De Beers’s response to the laboratory-grown diamond category is the most revealing indicator of how the incumbent industry has assessed the long-term competitive dynamic. In 2018, De Beers launched Lightbox — a laboratory-grown diamond brand — at deliberately aggressive pricing ($800 per carat, fixed across quality grades) with the explicit goal of price-anchoring the laboratory-grown category at consumer levels that would prevent it from cannibalizing natural diamond bridal sales.
The strategic logic was clear: by establishing Lightbox as a fashion jewelry brand at accessible price points, De Beers aimed to define laboratory-grown diamonds as a separate, lower-prestige category rather than allowing them to position as natural diamond substitutes at a discount. The messaging was explicit: Lightbox materials communicated that laboratory diamonds are “a beautiful product, but not a precious one” — an attempt to preemptively deny the category the scarcity narrative that underpins natural diamond pricing.
The results have been mixed. Lightbox achieved meaningful retail penetration and contributed to price compression in the fashion jewelry segment. But laboratory-grown diamonds have continued to expand upmarket, with bridal and fine jewelry retailers increasingly offering laboratory-grown options alongside natural diamonds at dramatically lower price points. The bridal category — historically the most important driver of natural diamond demand — has seen laboratory-grown penetration estimates ranging from ten to thirty percent in North American and UK retail, depending on price segment and retailer positioning.
De Beers’s response evolved: in 2023, the company began significantly reducing its own laboratory-grown production costs and expanded Lightbox’s reach while simultaneously intensifying its marketing investment in the “real is rare” natural diamond narrative through its Natural Diamond Council collaborations.
Collector and Investor Sentiment: Where the Divergence Is Sharpest
Among sophisticated collectors and investors in natural diamonds, sentiment toward laboratory-grown stones is largely consistent: they are consumer products, not investment assets, and their price trajectory confirms this assessment. The case is straightforward.
Collectible investment assets derive their value from genuine scarcity — a property laboratory-grown diamonds categorically lack. A laboratory-grown diamond of any size and quality can be reproduced to exact specifications an unlimited number of times, given sufficient production capacity. The supply curve is elastic with respect to demand in a way that natural diamonds — particularly exceptional natural diamonds — are not. This distinction, which is fundamental to any investment asset framework, means laboratory-grown diamonds cannot serve as stores of value in the way that fine natural diamonds have historically.
The secondary market data confirms this intuition. Laboratory-grown diamonds trade at significant discounts to original retail prices in resale, and the discounts have grown as the retail price has compressed. A laboratory-grown diamond purchased in 2019 for $3,000 would likely trade in 2025 secondary markets for $200 to $400 — representing a capital loss of eighty-five to ninety percent. For natural diamonds of comparable quality and appropriate size, secondary market performance over the same period has been meaningfully positive, particularly for exceptional qualities.
The collector community’s response has also included a pricing realignment toward the genuinely rare: stones above three carats in D-F color and VVS or better clarity, Fancy Vivid colored diamonds, exceptional Kashmir sapphires and Burmese rubies — assets whose scarcity cannot be synthetically replicated. Laboratory-grown diamonds have, paradoxically, reinforced the investment case for the upper tier of the natural diamond market by demonstrating clearly that only irreproducible rarity commands a sustainable price premium.
The Investment Implication: What Matters Now
For the serious natural diamond allocator, the laboratory-grown disruption has produced three actionable clarifications.
First, the near-colorless (G-J) natural diamond range at one to two carats has been most severely impacted by laboratory-grown competition at retail, and its investment characteristics have deteriorated accordingly. The premium for these grades relative to laboratory-grown equivalents has narrowed significantly enough that they no longer represent compelling investment-grade acquisition.
Second, the exceptional natural diamond tiers — D-F colorless above three carats, Fancy Vivid colored diamonds, and significant Fancy Intense pinks and blues — have maintained or widened their separation from laboratory-grown pricing because their scarcity is genuine and their collector base is sophisticated enough to make this distinction clearly. These tiers are where serious allocation is concentrating.
Third, provenance and certification matter more than ever. A natural diamond with a current GIA Type IIa determination, a clean chain of title, and a documented history of auction appearances has more defensible investment characteristics in a world where synthetic substitutes are indistinguishable to casual inspection. The laboratory-grown era has made the documentation ecosystem around natural diamonds more valuable, not less.
The laboratory-grown diamond story is not over, and the commercial disruption it has caused to the mid-market natural diamond retail business is real and ongoing. But the investment case for truly exceptional natural diamonds rests on foundations — irreproducible geology, documented provenance, sophisticated collector demand — that no technology can replicate.
[ QUICK POLL // 60 SECONDS ]